FMEA Stock Overview
Provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Fresenius Medical Care AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €20.60 |
| 52 Week High | €20.80 |
| 52 Week Low | €16.40 |
| Beta | 0.85 |
| 11 Month Change | 5.10% |
| 3 Month Change | 21.18% |
| 1 Year Change | 15.08% |
| 33 Year Change | -21.97% |
| 5 Year Change | -36.81% |
| Change since IPO | 45.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| FMEA | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.1% | -0.02% |
| 1Y | 15.1% | 17.2% | 8.2% |
Return vs Industry: FMEA underperformed the German Healthcare industry which returned 17.2% over the past year.
Return vs Market: FMEA exceeded the German Market which returned 8.2% over the past year.
Price Volatility
| FMEA volatility | |
|---|---|
| FMEA Average Weekly Movement | 4.7% |
| Healthcare Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: FMEA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: FMEA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 113,079 | Helen Giza | www.freseniusmedicalcare.com |
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products.
Fresenius Medical Care AG Fundamentals Summary
| FMEA fundamental statistics | |
|---|---|
| Market cap | €12.40b |
| Earnings (TTM) | €658.94m |
| Revenue (TTM) | €19.24b |
18.8x
P/E Ratio0.6x
P/S RatioIs FMEA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FMEA income statement (TTM) | |
|---|---|
| Revenue | €19.24b |
| Cost of Revenue | €14.40b |
| Gross Profit | €4.84b |
| Other Expenses | €4.18b |
| Earnings | €658.94m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 25, 2025
| Earnings per share (EPS) | 2.25 |
| Gross Margin | 25.14% |
| Net Profit Margin | 3.43% |
| Debt/Equity Ratio | 49.4% |
How did FMEA perform over the long term?
See historical performance and comparison